Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beinaglutide plus lifestyle intervention for overweight or obesity in adults
ChiCTR1900023428Phase 3Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Beinaglutide with Placebo (2 arms). Primary endpoints: Difference from placebo in mean percentage body weight loss from baseline at Week 16 and Proportion of subjects with at least 5% body weight reduction from baseline at Week 16. Started Apr 2019; status: recruiting.
02
Drugs
beinaglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on ChiCTR1900023428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023428.